Overview
- FDA, which posted its notice Wednesday, scheduled July 23–24 advisory meetings to consider whether seven peptides can be made by compounding pharmacies.
- The panel will review BPC-157, KPV, TB-500, MOTS-C, emideltide, semax, and epitalon, with a separate session planned to examine five more peptides before February 2027.
- The committee’s recommendations are not binding, and any change would still require formal FDA rulemaking before compounding pharmacies could legally produce these substances.
- Regulators barred many peptides from compounding in 2023 over safety concerns such as immune reactions, organ toxicity, and possible cancer risks, and public-health experts say rigorous human trials remain scarce.
- HHS Secretary Robert F. Kennedy Jr. has promoted broader access and says he uses peptides, while critics warn against politicizing the review and urge use of the standard drug-approval pathway as investors bid up Hims & Hers on the prospect of future, regulated sales.